2024年4月，全球医药市场共签署了28笔资产授权和合作协议，与3月份的40笔相比减少了30%。其中，中国医药市场共达成7笔交易，包括1笔出海交易、3笔引进交易和3笔国内交易。本月中国市场最重要的交易来自翰森制药与荃信生物达成的交易，首付款1100万美元，总价值1.56亿美元。
全球范围内，4月份共签署了21项资产授权和合作协议。最大的一笔交易是Novartis与Arvinas就两款靶向AR PROTAC达成的交易，首付款1.5亿美元，总价值11.6亿美元。
In April, a total of 28 licensing and cooperation deals were signed globally. In the China Biotech Industry, 7 licensing and cooperation deals were specifically sealed: 1 out-licensing deal, 3 in-licensing deals, and 3 domestic deals. The highlight deal of the month is the domestic deal between Qyuns Therapeutics and Hansoh Pharmaceutical, amounting to $156 million with an upfront payment of $11 million.
On the global scale, there were a total of 21 global licensing and cooperation deals signed in April. The most prominent global deal was the deal between Arvinas and Novartis for Luxdegalutamide and AR-V7 PROTAC with a total deal value of $1,160 million and an upfront payment of $150 million.
2b. In-Licensing Deals
2c. Domestic Licensing Deals
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Partnering Forum @BIO
Date & Time: June 3-20, 2024
Venue: San Diego & Online
Content: Keynote Speeches, Panel Discussion, Virtual Roadshows, Dinner Reception, 1X1 meetings
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs.
